Biotech News

Sight Sciences to Report Third Quarter 2026 Financial Results on November 4, 2026

Sight Sciences (SGHT)Sight Sciences2026-10-21 20:05 ESTEarnings

MENLO PARK, Calif., Oct. 21, 2026 (GLOBE NEWSWIRE) -- Sight Sciences, Inc. (Nasdaq: SGHT) (Sight Sciences or the Company), an eyecare technology company focused on developing and commercializing innovative, interventional technologies intended to transform care and improve patients' lives, today

Related news

CVRXCVRx2026-10-22 20:30 EST

CVRx to Report Third Quarter 2026 Financial and Operating Results and Host Conference Call on November 5, 2026

OMOutset Medical2026-10-21 20:05 EST

Outset Medical to Report Third Quarter 2026 Financial Results on Wednesday, November 4, 2026

RXSTRxSight2026-10-20 20:05 EST

RxSight, Inc. to Report Third Quarter 2026 Financial Results on November 3

STXSStereotaxis2026-10-20 11:40 EST

Stereotaxis to Report Third Quarter 2026 Financial Results on November 10, 2026

IRTCiRhythm2026-10-15 20:05 EST

iRhythm Holdings to Report Third Quarter 2026 Financial Results on November 5, 2026

ADPTAdaptive Biotechnologies2026-10-14 20:05 EST

Adaptive Biotechnologies to Report Third Quarter 2026 Financial Results on November 4, 2026

PRCTPROCEPT BioRobotics2026-10-12 20:05 EST

PROCEPT BioRobotics® to Report Third Quarter 2026 Financial Results on November 4th, 2026

PLSEPulse Biosciences2026-10-22 20:05 EST

Pulse Biosciences Schedules Third Quarter 2026 Financial Results Conference Call for November 5, 2026

OCGNOcugen2026-10-22 11:00 EST

Ocugen to Provide Business Update and Third Quarter 2026 Financial Results on November 4

TCMDTactile Systems Technology, Inc.2026-10-19 20:05 EST

Tactile Medical to Release Third Quarter of Fiscal Year 2026 Financial Results on November 2, 2026

View all latest news

Sight Sciences

Interventional Eye Care Sight Sciences develops minimally invasive and noninvasive technologies intended to address underlying causes of glaucoma and dry-eye disease. Glaucoma Systems OMNI and OMNI Edge are implant-free minimally invasive glaucoma-surgery systems that access Schlemm's canal and the trabecular meshwork. SION is a...

Recent company news

SGHTSight Sciences2026-10-21 20:05 EST

Sight Sciences to Report Third Quarter 2026 Financial Results on November 4, 2026

SGHTSight Sciences2026-10-01 11:05 EST

Sight Sciences to Debut the OMNI Ultra® Surgical System, the Latest Technology Advancement from the Pioneers of Ab Interno Canaloplasty, at the 2026 American Academy of Ophthalmology (AAO) Annual Meeting

SGHTSight Sciences2026-09-01 20:05 EST

Sight Sciences to Present at the Upcoming Morgan Stanley Global Healthcare Conference on September 15

SGHTSight Sciences2026-08-19 11:05 EST

TearCare Becomes the First and Only MGD Treatment Indicated to Improve Meibomian Gland Function in Patients with Evaporative Dry Eye Disease

SGHTSight Sciences2026-08-05 20:05 EST

Sight Sciences Reports Second Quarter 2026 Financial Results

Stock data

Close: 8.70 USD
Market cap: 236.14M USD
Exchange: NASDAQ
Sector: MedTech
Location: United States